since IPO. I think comms are the usual but transparent. Keeping an eye on cash runway and delivery of milestones to see if they deliver - so far so good.
510k applications don’t have a good track record for ASX bios hopefully this is about to change. AYA is another with FDA decision due this month.
Ann: COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark, page-24
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add COV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.0¢ |
Change
0.015(4.48%) |
Mkt cap ! $28.56M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 35.0¢ | 33.0¢ | $20.93K | 61.54K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 50293 | 2 |
View Market Depth
| Last trade - 15.53pm 07/08/2024 (20 minute delay) ? |
| COV (ASX) Chart |